Enliven Therapeutics (Enliven Therapeutics) ROCE % : -36.88% (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Enliven Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Enliven Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2024 was -36.88%.

Enliven Therapeutics ROCE % Historical Data

The historical data trend for Enliven Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enliven Therapeutics ROCE % Chart

Enliven Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

ROCE %

-7.19

-20.89

-42.83

-52.28

Enliven Therapeutics Quarterly Data
	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial							-35.93	-28.20	-35.84	-35.80	-36.88

Enliven Therapeutics ROCE % Calculation

Enliven Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-83.529	/	( ( (83.298 - 9.715)	+	(271.867 - 25.894) )	/ 2 )
	=	-83.529	/	( (73.583	+	245.973)	/ 2 )
	=	-83.529	/	159.778
	=	-52.28 %

Enliven Therapeutics's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-103.948	/	( ( (271.867 - 25.894)	+	(342.777 - 25.031) )	/ 2 )
	=	-103.948	/	( ( 245.973	+	317.746 )	/ 2 )
	=	-103.948	/	281.8595
	=	-36.88 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Enliven Therapeutics (NAS:ELVN) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Enliven Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Enliven Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Enliven Therapeutics (Enliven Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enliven Therapeutics Inc (NAS:ELVN) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

6200 Lookout Road, Boulder, CO, USA, 80301

Website

https://www.enliventherapeutics.com

Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially best-in-class or first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases.

Executives

Anish Patel	officer: Chief Operating Officer	C/O ENLIVEN THERAPEUTICS INC, 6200 LOOKOUT ROAD, BOULDER CO 80301
Benjamin Hohl	officer: Chief Financial Officer	6200 LOOKOUT ROAD, BOULDER CO 80301
Joseph P Lyssikatos	director, officer: Chief Scientific Officer	6200 LOOKOUT ROAD, BOULDER CO 80301
Samuel Kintz	director, officer: President and CEO	ENLIVEN THERAPEUTICS INC, 6200 LOOKOUT ROAD, BOULDER CO 80301
Richard A. Heyman	director	5871 OBERLIN DRIVE, SUITE 150, SAN DIEGO CA 92121
5am Partners Vi, Llc	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Rishi Gupta	director, 10 percent owner	C/O CHEMOCENTRYX, INC., 850 MAUDE AVENUE, MOUNTAIN VIEW CA 94043
Andrew J. Schwab	director	C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Helen Louise Collins	director	TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Jake Bauer	director	C/O MYOKARDIA, INC., 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
5am Opportunities I, L.p.	10 percent owner	501 SECOND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Opportunities I (gp), Llc	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Orbimed Genesis Gp Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Kush Parmar	10 percent owner	C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Ventures Vi, L.p.	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107

Enliven Therapeutics (Enliven Therapeutics) Headlines

From GuruFocus

Enliven Therapeutics Inc CFO Benjamin Hohl Sells 11,870 Shares

By GuruFocus Research • 01-03-2024

Enliven Therapeutics Highlights Business Achievements and Reports First Quarter 2023 Financial Results

By sperokesalga sperokesalga • 05-11-2023

Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

By Marketwired • 08-10-2023

Enliven Therapeutics to Present at Two Upcoming Investor Conferences

By sperokesalga sperokesalga • 05-31-2023